Taiwan launches safety watch for MS drug

NCT ID NCT04480853

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to monitor the safety of fingolimod (Gilenya) in Taiwanese adults newly starting this medication for relapsing-remitting multiple sclerosis. Thirty-four participants will take the daily medication for one year while researchers track side effects and health changes. The study focuses on identifying potential heart, liver, and blood-related side effects that might occur during treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site
RECRUITING

Taichung, 407219, Taiwan
Novartis Investigative Site
WITHDRAWN

Tainan, 704302, Taiwan
Novartis Investigative Site
RECRUITING

Taipei, 10002, Taiwan
Novartis Investigative Site
WITHDRAWN

Taipei, 11220, Taiwan
Novartis Investigative Site
WITHDRAWN

Taoyuan District, 33305, Taiwan

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS